<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seventeen consecutively admitted poor risk <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients and 4 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) were treated with a remission-induction regimen consisting of a 7-day continuous intravenous infusion of conventional doses of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and of three 24-h constant rate infusions of <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> administered intermittently on days 1, 3 and 5 </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnoses were: relapsed primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in 6 patients, <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> in 11 patients (9 untreated, 2 relapsed) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in 4 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The median age was 50 yr </plain></SENT>
<SENT sid="3" pm="."><plain>Five of 6 patients with relapsed primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 3 of 11 patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> and 2 of 4 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> achieved complete remission (CR) </plain></SENT>
<SENT sid="4" pm="."><plain>The overall CR rate was 48% with a median remission duration of 5 months (range: 0.25-20 months) </plain></SENT>
<SENT sid="5" pm="."><plain>Few <z:hpo ids='HP_0011009'>acute</z:hpo> toxic side effects were observed thanks to the constant rate of infusion of <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> </plain></SENT>
</text></document>